Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Analysts were generally positive about the latest development, too. Following quite encouraging news from the laboratory on ...

"No other day of the year exhibits this amount of across-the-board strength," writes Stock Trader's Almanac Editor Jeffrey ...

The Dow Dow Jones Industrial Average was most recently trading 492 points higher (1.1%), as shares of Amgen Amgen Inc. and Merck Merck & Co. Inc. have contributed around 25% of the blue-chip gauge's ...

Buoyed by positive gains for shares of Amgen and Merck, the Dow Jones Industrial Average is climbing Tuesday morning. Supported by world-class markets data from Dow Jones and FactSet, and partnering ...

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Mirae Asset Global Investments trimmed its Amgen holdings by 1.5% in the first quarter, selling 7,398 shares. This reduction ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Bessemer Group Inc. reduced its Amgen stake by 39.3% in the first quarter, selling over 15,000 shares. Other institutional ...

Amgen Inc. (NASDAQ: AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, ...

To get a sense of who is truly in control of Amgen Inc. (NASDAQ:AMGN), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...